Skip to main content
Erschienen in: Journal of Genetic Counseling 1/2008

01.02.2008 | Original Research

Diagnosis of Fabry Disease via Analysis of Family History

verfasst von: Dawn A. Laney, Paul M. Fernhoff

Erschienen in: Journal of Genetic Counseling | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Fabry disease is an X-linked lysosomal storage condition caused by a deficiency of α-galactosidase A. In order to determine the average number of family members who are diagnosed with Fabry disease following the diagnosis of a proband, four lysosomal storage disease centers across the United States reviewed the completed pedigrees of their Fabry disease patients. In addition, data from three Fabry disease families from other centers were submitted by patients directly. The pedigree review found 74 probands (54 males and 20 females) who had 357 diagnosed family members, of which 223 were female (60.5%) and 146 were male (39.5%). Analysis found that, on average, there were five family members diagnosed with Fabry disease for every proband. Now that enzyme replacement therapy (ERT) is available for the treatment of Fabry disease, this finding emphasizes the need for all health care professionals to ensure a detailed pedigree has been constructed for each patient affected by Fabry disease and to encourage testing and evaluation of all at-risk family members.
Literatur
Zurück zum Zitat Bennett, R. L., Hart, K. A., O’Rourke, E. O., Barranger, J. A., Johnson, J., & MacDermot, K. D., et al. (2002). Fabry disease in genetic counseling practice: Recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 11(2), 121–146.PubMedCrossRef Bennett, R. L., Hart, K. A., O’Rourke, E. O., Barranger, J. A., Johnson, J., & MacDermot, K. D., et al. (2002). Fabry disease in genetic counseling practice: Recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 11(2), 121–146.PubMedCrossRef
Zurück zum Zitat Brady, R. O., Murray, G. J., Moore, D. F., & Schiffmann, R. (2001). Enzyme replacement therapy in Fabry disease. Journal of Inherited Metabolic Disease 18–24. Brady, R. O., Murray, G. J., Moore, D. F., & Schiffmann, R. (2001). Enzyme replacement therapy in Fabry disease. Journal of Inherited Metabolic Disease 18–24.
Zurück zum Zitat Deegan, P., Baehner, A. F., Barba-Romero, M. A., Hughes, D., Kampmann, C., & Beck, M. (2006). Natural history of Fabry disease in females in the Fabry Outcome Survey. Journal of Medical Genetics, 43, 347–352.PubMedCrossRef Deegan, P., Baehner, A. F., Barba-Romero, M. A., Hughes, D., Kampmann, C., & Beck, M. (2006). Natural history of Fabry disease in females in the Fabry Outcome Survey. Journal of Medical Genetics, 43, 347–352.PubMedCrossRef
Zurück zum Zitat Desnick, R. J., Brady, R., Barranger, J., Collins, A. J., Germain, D. P., & Goldman, M., et al. (2003). Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Annals of Internal Medicine, 138, 338–346.PubMed Desnick, R. J., Brady, R., Barranger, J., Collins, A. J., Germain, D. P., & Goldman, M., et al. (2003). Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Annals of Internal Medicine, 138, 338–346.PubMed
Zurück zum Zitat Desnick, R. J., Ioannou, Y., & Eng, C. M. (2001). a-galactosidase A deficiency: Fabry disease. In C. R. Scriver, A. L. Beaudet, W. S. Sly, & D. Valle (Eds.) The metabolic and molecular bases of inherited disease (vol. 3, (pp. 3733–3774)8th ed.). New York: McGraw-Hill. Desnick, R. J., Ioannou, Y., & Eng, C. M. (2001). a-galactosidase A deficiency: Fabry disease. In C. R. Scriver, A. L. Beaudet, W. S. Sly, & D. Valle (Eds.) The metabolic and molecular bases of inherited disease (vol. 3, (pp. 3733–3774)8th ed.). New York: McGraw-Hill.
Zurück zum Zitat Eng, C. M., Germain, D. P., Banikazemi, M., Warnock, D. G., Wanner, C., & Hopkin, R. J., et al. (2006). Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement. Genetics in Medicine, 8(9), 539–548.PubMedCrossRef Eng, C. M., Germain, D. P., Banikazemi, M., Warnock, D. G., Wanner, C., & Hopkin, R. J., et al. (2006). Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement. Genetics in Medicine, 8(9), 539–548.PubMedCrossRef
Zurück zum Zitat Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., & Waldek, S., et al. (2001). Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry’s disease. New England Journal of Medicine, 345, 9–16.PubMedCrossRef Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., & Waldek, S., et al. (2001). Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry’s disease. New England Journal of Medicine, 345, 9–16.PubMedCrossRef
Zurück zum Zitat Fabry Registry (2007) Fabry Registry Aggregate Data Annual Report (RADAR). 2007. p. 1. Fabry Registry (2007) Fabry Registry Aggregate Data Annual Report (RADAR). 2007. p. 1.
Zurück zum Zitat Gupta, S., Ries, M., Kotsopoulos, S., & Schiffmann, R. (2005). The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: A cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine, 84, 261–268.PubMedCrossRef Gupta, S., Ries, M., Kotsopoulos, S., & Schiffmann, R. (2005). The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: A cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine, 84, 261–268.PubMedCrossRef
Zurück zum Zitat MacDermot, K. D., Holmes, A., & Miners, A. H. (2001). Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. Journal of Medical Genetics, 38, 769–775.PubMedCrossRef MacDermot, K. D., Holmes, A., & Miners, A. H. (2001). Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. Journal of Medical Genetics, 38, 769–775.PubMedCrossRef
Zurück zum Zitat Mehta, A., Ricci, R., Widmer, U., Dehout, F., Garcia de Lorenzo, A., & Kapmann, C., et al. (2004). Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry outcome survey. European Journal of Clinical Investigation, 34(3), 236–242.PubMedCrossRef Mehta, A., Ricci, R., Widmer, U., Dehout, F., Garcia de Lorenzo, A., & Kapmann, C., et al. (2004). Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry outcome survey. European Journal of Clinical Investigation, 34(3), 236–242.PubMedCrossRef
Zurück zum Zitat Spada, M., Pagliardini, S., Yasuda, M., Tukel, T., Thiagarajan, G., & Sakuraba, H., et al. (2006). High incidence of later-onset Fabry disease revealed by newborn screening. American Journal of Human Genetics, 79(1), 31–40.PubMedCrossRef Spada, M., Pagliardini, S., Yasuda, M., Tukel, T., Thiagarajan, G., & Sakuraba, H., et al. (2006). High incidence of later-onset Fabry disease revealed by newborn screening. American Journal of Human Genetics, 79(1), 31–40.PubMedCrossRef
Zurück zum Zitat Street, N. J., Yi, M. S., Bailey, L. A., & Hopkin, R. J. (2006). Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease. Genetics in Medicine, 8(6), 346–353.PubMedCrossRef Street, N. J., Yi, M. S., Bailey, L. A., & Hopkin, R. J. (2006). Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease. Genetics in Medicine, 8(6), 346–353.PubMedCrossRef
Zurück zum Zitat Wang, R. Y., Lelis, A., Mirocha, J., & Wilcox, W. R. (2007). Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genetics in Medicine, 9(1), 34–45.PubMedCrossRef Wang, R. Y., Lelis, A., Mirocha, J., & Wilcox, W. R. (2007). Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genetics in Medicine, 9(1), 34–45.PubMedCrossRef
Zurück zum Zitat Whybra, C., Kampmann, C., Willers, I., & Davies, J., et al. (2001). Anderson-Fabry disease: Clinical manifestations of disease in female heterozygotes. Journal of Inherited Metabolic Disease, 24, 715–724.PubMedCrossRef Whybra, C., Kampmann, C., Willers, I., & Davies, J., et al. (2001). Anderson-Fabry disease: Clinical manifestations of disease in female heterozygotes. Journal of Inherited Metabolic Disease, 24, 715–724.PubMedCrossRef
Metadaten
Titel
Diagnosis of Fabry Disease via Analysis of Family History
verfasst von
Dawn A. Laney
Paul M. Fernhoff
Publikationsdatum
01.02.2008
Verlag
Springer US
Erschienen in
Journal of Genetic Counseling / Ausgabe 1/2008
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-007-9128-x

Weitere Artikel der Ausgabe 1/2008

Journal of Genetic Counseling 1/2008 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.